New blood pressure combo pill aims to beat standard treatment
NCT ID NCT06643819
First seen Dec 29, 2025 · Last updated Jun 23, 2026 · Updated 30 times
Summary
This phase 3 trial tests whether a combination pill containing sacubitril and valsartan (CKD-202A) works better than valsartan alone for essential hypertension. About 324 adults with high blood pressure will take either the combo or the standard drug for 10 weeks. The main goal is to see if the combo lowers average systolic blood pressure more effectively.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESSENTIAL HYPERTENSION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Wonju Severance Christian Hospital
RECRUITINGWŏnju, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Sacubitril/valsartan (a combination drug that helps relax blood vessels and reduce fluid buildup)
What this could lead to
If successful, this could provide a more effective once-daily pill for controlling high blood pressure compared to current standard treatments.
What could go wrong
This is a confirmatory phase 3 trial, but the drug is already approved for heart failure; its superiority over valsartan alone for hypertension is not guaranteed. Side effects like low blood pressure or dizziness are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.